Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cu(II)ATSM in early Parkinson's disease
NCT03204929Phase 1Completed
- Sponsor
- Vivat Therapeutics
- Start
- Aug 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CuATSM in Parkinson's disease (PD), sponsored by Vivat Therapeutics. Primary endpoint: Recommended phase 2 dose at 6 months. Started Aug 2017; status: completed.
02
Drugs
CuATSM
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03204929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03204929.